Launching RamaX: ultra-fast binder screening at scale. As part of its mission to make binder discovery faster, more accurate, and more accessible than ever before, Diffuse has invented a new assay to accelerate experimental validation of binders at scale. Today Diffuse is launching RamaX, its platform for ultra-fast, high-sensitivity screening of thousands to billions of minibinders, VHHs, and scFvs. Where traditional workflows take months, RamaX enables Diffuse to deliver validated binders from naive or AI-designed libraries in just 1-2 weeks. Why RamaX matters. As protein generative methods improve, experimental screening becomes the rate-limiting step. Diffuse needed a faster way to accurately detecting functional protein designs - including in regimes where expected success rates are <1%. Similar to its rationale for training better protein foundation models, which enable a multitude of computational protein design tasks, Diffuse developed RamaX as a new detection methodology which accelerates many experimental workflows. This advance in speed and throughput comes from a new assay that intrinsically supports large-scale screening, rather than lab automation of inefficient existing protocols. High-capacity, ultra-rapid screening protocols raise the ceiling for protein discovery. RamaX expands its ability to identify binders against increasingly challenging targets, while generating the massive biological datasets that will power its next generation of de novo protein design models. Technical details and results. Diffuse discuss RamaX's capabilities, performance benchmarks, and technical specifications in its full technical report. Here's a quick summary of the key results: * Size: Diffuse used RamaX to screen ~80K AI-designed VHHs, and a ~1e9 naive VHH library * Speed: library screening, ordering designs to test on SPR, and arriving at validated binders and affinities takes 1-2 weeks. * Sensitivity: RamaX detected binders with affinities ranging from 100pM - 1uM, including pulling out several binders that failed to enrich on yeast surface display. * Selectivity: RamaX recovered target-specific binders while performing multiplex screening against 5many antigens simultaneously. Getting started with RamaX. Switching from yeast surface display (YSD) to RamaX for its internal campaigns has completely transformed its ability to screen and learn from AI-designed libraries. RamaX can also enable rapid, large-scale screening for many other binder discovery workflows. Diffuse is excited to put RamaX into your hands as a screening service to accelerate fast binder discovery at scale. * RamaX Screen: Bring your own binder libraries for rapid screening * RamaX Discovery: Discover antibodies or VHHs from naive binder libraries and AI-designed libraries View its full list of RamaX offerings and pricing on its website. What's next. Improvements are underway to increase parallel antigen screening capacity and expand to applications beyond binder identification. For example, prediction and control over multimodal developability properties remains challenging. Diffuse envision using future extensions of RamaX to collect large-scale data to solve downstream challenges in drug candidate development. Developing new infrastructure like RamaX represents a key milestone in its vision: seamlessly integrating AI protein design with experimental validation to accelerate therapeutic discovery. If this excites you, Diffuse encourage you to get in touch to explore partnership opportunities, learn more about RamaX, or work with Diffuse by joining its team.

Comics software, meat-based plants and Tesla spun-out heat pumps, anyone?